Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Response of COVID-19 vaccination in multiple sclerosis patients following disease-modifying therapies: A meta-analysis
Xi Wu, Lu Wang, Lu Shen, et al.
EBioMedicine (2022) Vol. 81, pp. 104102-104102
Open Access | Times Cited: 51

Showing 1-25 of 51 citing articles:

S1PR1 inhibition induces proapoptotic signaling in T cells and limits humoral responses within lymph nodes
Dhaval Dixit, Victoria M. Hallisey, Ethan Y.S. Zhu, et al.
Journal of Clinical Investigation (2024) Vol. 134, Iss. 4
Open Access | Times Cited: 7
B cell targeted therapies in inflammatory autoimmune disease of the central nervous system
Moritz J. Furman, Sven G. Meuth, Philipp Albrecht, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 20
Autologous haematopoietic stem cell transplantation for treatment of multiple sclerosis and neuromyelitis optica spectrum disorder — recommendations from ECTRIMS and the EBMT
Paolo A. Muraro, Alice Mariottini, Raffaella Greco, et al.
Nature Reviews Neurology (2025)
Closed Access
Efficacy, immunogenicity, and safety of the Novavax COVID-19 vaccine in immunocompromised patients: A targeted literature review
Manuela H Gschwend, Anthony M. Marchese, Dirk Poelaert, et al.
Vaccine (2025) Vol. 49, pp. 126777-126777
Open Access
Analysis of Rituximab Use, Time Between Rituximab and SARS-CoV-2 Vaccination, and COVID-19 Hospitalization or Death in Patients With Multiple Sclerosis
Jessica B. Smith, Edlin Gonzales, Bonnie H. Li, et al.
JAMA Network Open (2022) Vol. 5, Iss. 12, pp. e2248664-e2248664
Open Access | Times Cited: 26
Discovery and Preclinical Characterization of BIIB129, a Covalent, Selective, and Brain-Penetrant BTK Inhibitor for the Treatment of Multiple Sclerosis
Martin Himmelbauer, Bekim Bajrami, Rebecca Basile, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 10, pp. 8122-8140
Open Access | Times Cited: 4
The impact of sphingosine-1-phosphate receptor modulators on COVID-19 and SARS-CoV-2 vaccination
David Baker, Eugenia Forte, Gareth Pryce, et al.
Multiple Sclerosis and Related Disorders (2022) Vol. 69, pp. 104425-104425
Open Access | Times Cited: 19
A Review Pertaining to SARS-CoV-2 and Autoimmune Diseases: What Is the Connection?
Nina Kocivnik, Tomaž Velnar
Life (2022) Vol. 12, Iss. 11, pp. 1918-1918
Open Access | Times Cited: 18
Consensus statement of the Spanish Society of Neurology on the treatment of multiple sclerosis and holistic patient management in 2023
José Meca-Lallana, Sergio Martínez‐Yélamos, Sara Eichau, et al.
Neurología (English Edition) (2024) Vol. 39, Iss. 2, pp. 196-208
Open Access | Times Cited: 3
Summary of safety and efficacy of COVID-19 vaccination in patients with multiple sclerosis
Eva Pernicová, Petra Macounová, Martin Krsek, et al.
European Neurology (2023) Vol. 86, Iss. 4, pp. 263-276
Open Access | Times Cited: 9
mRNA versus inactivated virus COVID-19 vaccines in multiple sclerosis: Humoral responses and protectivity—Does it matter?
Melih Tütüncü, Serkan Demir, Gökhan Arslan, et al.
Multiple Sclerosis and Related Disorders (2023) Vol. 75, pp. 104761-104761
Open Access | Times Cited: 7
Immune Response to SARS-CoV-2 mRNA Vaccines in an Open-Label Multicenter Study in Participants with Relapsing Multiple Sclerosis Treated with Ofatumumab
Tjalf Ziemssen, Marie Groth, Benjamin Ettle, et al.
Vaccines (2022) Vol. 10, Iss. 12, pp. 2167-2167
Open Access | Times Cited: 11
COVID-19: The Course, Vaccination and Immune Response in People with Multiple Sclerosis: Systematic Review
Marcin Bazylewicz, Monika Gudowska-Sawczuk, Barbara Mroczko, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 11, pp. 9231-9231
Open Access | Times Cited: 5
Analysis of seroconversion following COVID-19 vaccination among multiple sclerosis patients treated with disease-modifying therapies in Poland
Aleksandra Podlecka‐Piętowska, Janusz Sierdziński, Monika Nojszewska, et al.
Neurologia i Neurochirurgia Polska (2024) Vol. 58, Iss. 1, pp. 112-119
Open Access | Times Cited: 1
Implications of disease-modifying therapies for multiple sclerosis on immune cells and response to COVID-19 vaccination
Valeria Orrù, Valentina Serra, Michele Marongiu, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 1
Factors Influencing COVID-19 Vaccine Hesitancy among Patients with Serious Chronic Illnesses during the Initial Australian Vaccine Rollout: A Multi-Centre Qualitative Analysis Using the Health Belief Model
Tammie Choi, Bryan Chan, Lisa Grech, et al.
Vaccines (2023) Vol. 11, Iss. 2, pp. 239-239
Open Access | Times Cited: 4
In-depth characterization of long-term humoral and cellular immune responses to COVID-19m-RNA vaccination in multiple sclerosis patients treated with teriflunomide or alemtuzumab
Anat Achiron, Mathilda Mandel, Sapir Dreyer-Alster, et al.
Multiple Sclerosis and Related Disorders (2023) Vol. 72, pp. 104616-104616
Open Access | Times Cited: 4
Results on SARS-CoV-2 mRNA Vaccine Booster from an Open-Label Multicenter Study in Ofatumumab-Treated Participants with Relapsing Multiple Sclerosis
Tjalf Ziemssen, Eugen Schlegel, Marie Groth, et al.
Vaccines (2023) Vol. 11, Iss. 5, pp. 978-978
Open Access | Times Cited: 4
Documento de consenso de la Sociedad Española de Neurología sobre el tratamiento de la esclerosis múltiple y manejo holístico del paciente 2023
José Meca-Lallana, Sergio Martínez‐Yélamos, Sara Eichau, et al.
Neurología (2024) Vol. 39, Iss. 2, pp. 196-208
Open Access | Times Cited: 1
Comparing the Impact of COVID-19 on Vaccinated and Unvaccinated Patients Affected by Myasthenia Gravis
Elena Scarsi, Sara Massucco, Pilar M. Ferraro, et al.
Life (2023) Vol. 13, Iss. 4, pp. 1064-1064
Open Access | Times Cited: 3
Era of COVID-19 in Multiple Sclerosis Care
Jonathan D. Krett, Amber Salter, Scott D. Newsome
Neurologic Clinics (2023) Vol. 42, Iss. 1, pp. 319-340
Open Access | Times Cited: 3
COVID‐19 vaccination and relapse activity: A nationwide cohort study of patients with multiple sclerosis in Denmark
Dominika Šťastná, Frederik Elberling, Luigi Pontieri, et al.
European Journal of Neurology (2023) Vol. 31, Iss. 3
Open Access | Times Cited: 3
A specific anti‐COVID‐19 BNT162b2 vaccine‐induced early innate immune signature positively correlates with the humoral protective response in healthy and multiple sclerosis vaccine recipients
Martina Severa, Fabiana Rizzo, Alessandro Sinigaglia, et al.
Clinical & Translational Immunology (2023) Vol. 12, Iss. 3
Open Access | Times Cited: 2
SARS‐CoV‐2 vaccination and infection in ozanimod‐treated participants with relapsing multiple sclerosis
Bruce Cree, Rachel Maddux, Amit Bar‐Or, et al.
Annals of Clinical and Translational Neurology (2023) Vol. 10, Iss. 10, pp. 1725-1737
Open Access | Times Cited: 2
Vaccine response in people with multiple sclerosis treated with fumarates
Matthew Tremblay, Sandra Vukusic, Mathura Shanmugasundaram, et al.
Multiple Sclerosis Journal - Experimental Translational and Clinical (2023) Vol. 9, Iss. 3
Open Access | Times Cited: 2
Page 1 - Next Page

Scroll to top